What is the recommended dosing, monitoring, and management of ruxolitinib (Jakavi) in adult patients with polycythemia vera?

Ruxolitinib (Jakavi) for Polycythemia Vera: Dosing, Monitoring, and Management

Ruxolitinib is strongly recommended as second-line therapy for PV patients who are resistant to or intolerant of hydroxyurea, starting at 10 mg orally twice daily with dose adjustments based on blood counts and response. 1, 2

Indication and Patient Selection

Ruxolitinib is FDA and EMA-approved specifically for PV patients with:

• Inadequate response to hydroxyurea, OR
• Intolerance to hydroxyurea 1

The European LeukemiaNet strongly recommends ruxolitinib in this setting, though the recommendation for interferon alfa should be preferred in young patients requiring long-term treatment due to concerns about prolonged JAK inhibitor exposure 1.

Starting Dose

Start at 10 mg orally twice daily for all PV patients 2. This differs from myelofibrosis dosing, which is platelet-based.

Dose Titration and Optimization

Dose Increases

• Do NOT increase during the first 4 weeks of therapy 2
• After 4 weeks, may increase by 5 mg twice daily increments if:
  • Hematocrit control (HCT <45%) is not achieved
  • Platelet count remains ≥100 × 10⁹/L
  • Hemoglobin ≥10 g/dL
  • No dose reductions or interruptions in prior 4 weeks 2
• Maximum dose: 25 mg twice daily (though 15 mg twice daily is typically sufficient)

Critical Pitfall

Inadequate dosing (<10 mg twice daily at any time point) is independently associated with worse event-free survival (HR 1.94), including increased risk of thrombosis, progression to myelofibrosis, and death 3. Maintain at least 10 mg twice daily whenever possible.

Dose Reductions for Toxicity

Hematologic Toxicity (Table-Based Approach)

For Hemoglobin:

• Hgb 10-12 g/dL: Consider dose reduction to avoid interruption
• Hgb 8-10 g/dL: Reduce by 5 mg twice daily (if on 5 mg BID, reduce to 5 mg once daily)
• Hgb <8 g/dL: Interrupt dosing 2

For Platelets:

• Platelets 75-100 × 10⁹/L: Consider dose reduction
• Platelets 50-75 × 10⁹/L: Reduce by 5 mg twice daily
• Platelets <50 × 10⁹/L: Interrupt dosing 2

For Neutrophils:

• ANC <1.0 × 10⁹/L: Interrupt dosing 2

Restarting After Interruption

When restarting, use a dose at least 5 mg twice daily LOWER than the dose that caused interruption, with specific maximum restart doses based on recovery parameters 2:

• If Hgb ≥12 g/dL AND platelets ≥100 × 10⁹/L AND ANC ≥2.0 × 10⁹/L: Maximum restart 15 mg BID
• If Hgb 10-12 g/dL OR platelets 75-100 × 10⁹/L OR ANC 1.5-2.0 × 10⁹/L: Maximum restart 10 mg BID
• If Hgb 8-10 g/dL OR platelets 50-75 × 10⁹/L OR ANC 1.0-1.5 × 10⁹/L: Maximum restart 5 mg BID

Exception: Dose interruption due to phlebotomy-associated anemia does NOT require dose reduction upon restart 2.

Monitoring Schedule

Blood Count Monitoring

• Every 2-4 weeks until doses are stabilized 2
• Then as clinically indicated (typically monthly once stable)
• Monitor: Complete blood count with differential, hematocrit

Response Assessment at 6 Months

Three independent predictors of poor event-free survival should be assessed at baseline, 3 months, and 6 months 3:

1. Phlebotomy requirement: Presence at ≥2 time points predicts worse outcomes (HR 2.11)
2. Spleen response: Lack of ≥50% spleen length reduction at months 3 AND 6 predicts worse outcomes (HR 2.65)
3. Dose adequacy: Ruxolitinib <10 mg BID at ≥1 time point predicts worse outcomes (HR 1.94)

If patients have poor response at 6 months (high-risk PV-RR6 score >2.5), consider treatment optimization or alternative strategies, as 5-year event-free survival drops to 38.9% versus 89.4% in optimal responders 3.

Expected Outcomes and Treatment Goals

Hematocrit Control

• 60-62% achieve hematocrit control (HCT <45% without phlebotomy) by week 32 4, 5
• 85% of patients require no phlebotomies during treatment 6
• Target: Maintain HCT <45% at all times 1

Spleen Response

• 38% achieve ≥35% spleen volume reduction at week 32 4
• Spleen response is a critical predictor of long-term outcomes 3

Symptom Improvement

• 49% achieve ≥50% reduction in total symptom score at week 32 4

Molecular Response

• Mean JAK2V617F allele burden decreases from ~66% at baseline to ~41% at week 208 (4 years) 5

Safety Monitoring and Management

Common Adverse Events

Hematologic (most common):

• Anemia: 22.6% of patients, mostly grade 1-2 6
  • Grade 3-4 anemia: 2% 4
• Thrombocytopenia: Grade 3-4 in 5% 4

Infectious Complications:

• Herpes zoster: 6% of patients (all grade 1-2) 4
  • Consider prophylactic antiviral therapy (valacyclovir or acyclovir) in high-risk patients
  • Vaccination with recombinant zoster vaccine (Shingrix) is recommended before starting therapy when possible

Other Adverse Events:

• Hyperlipidemia: Monitor lipid panel periodically 7
• Non-melanoma skin cancer: Annual dermatologic surveillance 7

Thrombotic Events

Thrombotic events are REDUCED on ruxolitinib: Only 1 patient (0.9%) in the ruxolitinib arm versus 6 patients (5.4%) in standard therapy experienced thromboembolic events in RESPONSE 4. Real-world data confirms low rates (3.1-3.8%) 8.

Critical Safety Consideration

Treatment-related deaths are rare (2 of 350 patients in real-world study) 6. The safety profile is well-characterized and manageable with appropriate monitoring 7, 9.

Concomitant Therapy

Continue low-dose aspirin (75-100 mg daily) unless contraindicated 1. All PV patients should receive aspirin for thrombosis prevention.

Phlebotomy may still be needed initially but requirement should decrease significantly. Persistent phlebotomy need at multiple time points (baseline, 3 months, 6 months) indicates suboptimal response and warrants dose optimization 3.

Duration of Therapy

Ruxolitinib provides durable long-term control and should be continued indefinitely as long as benefit persists 9. The drug has now been used for over 10 years with well-characterized long-term safety 9.

Do NOT discontinue prematurely: Median treatment duration in studies exceeds 3-4 years with maintained efficacy 6, 5.

Treatment Failure

If inadequate response after 6 months despite optimal dosing (≥10 mg BID), consider:

• Switching to ropeginterferon alfa-2b (especially in younger patients)
• Clinical trial enrollment
• Combination strategies (investigational)

The evidence quality for ruxolitinib in PV is moderate overall, with high-level evidence for hematocrit response and primary response, but downgraded due to performance bias and indirectness in comparators in the RESPONSE trials 1.